Evonik Venture Capital
Evonik Venture Capital (EVC) is the corporate venture capital unit of German specialty chemicals group Evonik Industries, investing off the parent balance sheet since 2012. From offices in Germany, the USA and China it takes minority stakes of up to 15 million euros in start-ups across advanced and sustainable materials, health and precision biosolutions, the energy transition and enabling digital technologies, and it has made about 55 direct and fund investments. It also commits selectively to third-party venture funds as a limited partner and runs a dedicated Sustainability Tech Fund launched in 2022.
Evonik Venture Capital is an Essen venture capital firm with 20 active companies and 9 exits.
- ·5 exits in the last 5 years · consistent DPI cadence.
- ·Average hold across 9 realized deals: 5 years.
Sector breakdown
29 companiesGeography breakdown
12 geographiesKey facts
Recent exits
Evonik Venture Capital sold Vivasure Medical to Haemonetics in 2026 after 10 years.
Evonik Venture Capital sold Nanocomp to Radiant Opto-Electronics in 2023 after 8 years.
Evonik Venture Capital took FRX Polymers public in 2022 after 9 years.
Evonik Venture Capital sold CodeCheck to Producto GmbH in 2021 after 2 years.
Coverage notes
1 fund tracked, 29 portfolio companies (20 active · 9 realized). Verified weekly from public filings and deal announcements.
Funds & portfolio
Every fund Evonik Venture Capital has raised, with its portfolio companies. Hand-checked from public filings.
Evonik Venture CapitalActiveVC201220 assets9 exitsVC2012 · 14yr–209
Unrealized
20 held| Company | Entry |
|---|---|
| Abolis Biotech · France | 2024 |
| Allay Therapeutics MedTech · US | 2022 |
| Biograil MedTech · Denmark | 2022 |
| Castor Data & Analytics · Israel | 2019 |
| Circumfix Solutions MedTech · US | 2022 |
| Citrine Informatics AI/ML · US | 2022 |
| HPNow ClimateTech · Denmark | 2017 |
| In Ovo AgTech · Netherlands | 2018 |
| Interface Polymers Industrials · UK | 2023 |
| JLand Biotech Biotech · China | 2024 |
| Laxxon Medical Pharma · US | 2022 |
| Modern Meadow Biotech · US | 2019 |
| Nanotech Industrial Solutions Industrials · US | 2017 |
| Numaferm Biotech · Germany | 2017 |
| Revivo BioSystems Biotech · Singapore | 2021 |
| SmartAHC AgTech · China | 2020 |
| Strohm Energy · Netherlands | 2019 |
| SuperC ClimateTech · China | 2023 |
| UnionTech Industrials · China | 2020 |
| Velox Industrials · Israel | 2018 |
Realized
9 exits| Company | Entry | Exit | Type | Buyer | MOIC |
|---|---|---|---|---|---|
| Algal Scientific Biotech · US | 2014 | 2017 | Trade Sale | Kemin Industries | – |
| Biosynthetic Technologies Industrials · US | 2014 | 2018 | Trade Sale | Calumet Specialty Products Partners | – |
| CodeCheck Software · Switzerland | 2019 | 2021 | Trade Sale | Producto GmbH | – |
| FRX Polymers Industrials · US | 2013 | 2022 | IPO | – | – |
| JeNaCell Biotech · Germany | 2015 | 2021 | Trade Sale | Evonik Industries | – |
| Nanocomp Deep Tech · Finland | 2015 | 2023 | Trade Sale | Radiant Opto-Electronics | – |
| Structured Polymers Industrials · US | 2017 | 2019 | Trade Sale | Evonik Industries | – |
| Synoste MedTech · Finland | 2015 | 2020 | Trade Sale | Globus Medical | – |
| Vivasure Medical MedTech · Ireland | 2016 | 2026 | Trade Sale | Haemonetics | – |
About Evonik Venture Capital
Evonik Venture Capital is the corporate venture capital arm of Evonik Industries with €400 million of fund volume as of December 2024, headquartered in Essen, Germany with offices in the USA and China. The firm was founded in 2012 as the corporate venture capital arm of the Evonik Industries specialty chemicals group and operates as a wholly-owned subsidiary with 50 plus direct and fund investments since 2012.
Investment thesis
Evonik Venture Capital deploys capital through a single €400 million evergreen-style corporate vehicle, targeting early-stage to growth-stage direct equity plus fund-of-funds commitments with up to €15 million per portfolio company. The strategy invests to give a global specialty-chemicals corporate early access to sustainability and decarbonisation technologies adjacent to its core business. Sector focus spans advanced precision biosolutions, energy transition, circular economy, smart and new materials, nutrition and care and specialty additives. Geographic deployment spans Germany, USA and China with European and North American deal focus.
Recent activity
Recent realised exits include materials and biotech (2023, most recent on record). Recent acquisitions include CircumFix (medtech Series A, 2024) plus two new portfolio investments completed in 2024. The platform continues active deployment across the strategic specialty-chemicals venture thesis.
Frequently asked questions
- What investment strategy does Evonik Venture Capital focus on?
- Evonik Venture Capital focuses on VC strategies in the private equity space.
- How many portfolio companies does Evonik Venture Capital have?
- Evonik Venture Capital has 20 active portfolio companies and 9 completed exits and 1 fund tracked on GP Intel.
- Where is Evonik Venture Capital headquartered?
- Evonik Venture Capital is headquartered in Essen, Germany.
- When was Evonik Venture Capital founded?
- Evonik Venture Capital was founded in 2012.
- What sectors does Evonik Venture Capital invest in?
- Evonik Venture Capital invests across Industrials, Healthcare, Energy.
- What are Evonik Venture Capital's recent exits?
- Recent realized exits by Evonik Venture Capital include: Vivasure Medical (2026) to Haemonetics; Nanocomp (2023) to Radiant Opto-Electronics; CodeCheck (2021) to Producto GmbH; JeNaCell (2021) to Evonik Industries; Synoste (2020) to Globus Medical; Structured Polymers (2019) to Evonik Industries; Biosynthetic Technologies (2018) to Calumet Specialty Products Partners; Algal Scientific (2017) to Kemin Industries.
Similar firms
Other private equity firms tracked on GP Intel.
Germany·€300000.0B
Germany·€20.0B
Germany·€3.0B
Germany·€2.8B
Germany·€2.5B
Germany·€2.3B
Germany·€1.9B
Germany·€1.8B
Germany·€1.8B
Germany·€1.5B
Germany·€1.5B
Germany·€1.4B